Compare PW & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | SXTP |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.0M |
| IPO Year | 2011 | 2023 |
| Metric | PW | SXTP |
|---|---|---|
| Price | $8.00 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | 13.0K | ★ 69.3K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.90 | 36.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,982,265.00 | $1,005,471.00 |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.32 | ★ 65.49 |
| 52 Week Low | $0.50 | $0.34 |
| 52 Week High | $12.92 | $8.62 |
| Indicator | PW | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 37.45 |
| Support Level | $7.25 | $1.07 |
| Resistance Level | $11.62 | $1.62 |
| Average True Range (ATR) | 0.52 | 0.13 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 36.41 | 20.63 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.